Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

Clinical trial NCT05301010 · COMPLETED

Trial details

NCT number: NCT05301010
Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Cancer Metastatic Breast Cancer Recurrent Breast Cancer Female

Start date: 2018-02-02
Primary completion: 2021-02-19
Enrollment: 128

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.